Directorate Change

Sareum Holdings PLC
21 September 2007




                Sareum Holdings plc ("Sareum" or the "Company")


                                                              21 September 2007

                                 Board changes


Sareum Holdings plc is pleased to announce the appointment of Mr. Ernesto
Giorgio Reggiani to the Sareum Board with effect from 21 September 2007. As
announced on 18 June 2007, Mr. Reggiani was appointed as Finance Director in
June this year when it was anticipated that he would be invited to join the
board within three months. Mr. Reggiani is a Chartered Management Accountant
with 17 years of senior financial experience in companies including Esprit
Capital Partners LLP, Vidus Limited and Mobile Systems International plc.

The directors of Sareum believe that Mr. Reggiani brings a wide range of
experience to the board and consider him a valuable addition to the team.

Commenting on this announcement, Sareum's Chairman, Dr Paul Harper, said: "I am
delighted to announce that Giorgio has joined Sareum's Board. His strong record
of experience will be of great value to Sareum as we continue to advance all
elements of our business."

Mr. Reggiani is, or has been in the previous five years, a director or partner
of the following organisations:


Current directorships                 Previous directorships
Doppio LLP                            Esprit Capital Partners LLP
                                      Prelude Ventures Limited
                                      Interland Concepts Limited
                                      Confignium Limited


The Company confirms there is no other information that falls to be disclosed
under Schedule 2 paragraph (g) of the AIM Rules.



For further information:

Sareum Holdings plc                                       01223 497700
Tim Mitchell, Chief Executive Officer

Buchanan Communications                                  020 7466 5000
Tim Anderson, Mary-Jane Johnson

Grant Thornton Corporate Finance                         020 7383 5100
Philip Secrett, Colin Aaronson



Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange